For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Research and development | 9,340,959 | |||
| General and administrative | 10,492,554 | |||
| Total operating expenses | 19,833,513 | |||
| Loss from operations | -19,833,513 | |||
| Other income, net | 138,018 | |||
| Change in fair value of convertible promissory notes | -1,153,421 | |||
| Net loss | -20,848,916 | |||
| Basic EPS | -21.58 | |||
| Diluted EPS | -21.58 | |||
| Basic Average Shares | 966,124 | |||
| Diluted Average Shares | 966,124 | |||
Indaptus Therapeutics, Inc. (INDP)
Indaptus Therapeutics, Inc. (INDP)